Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 697-703

  Korst, Annelies E C ^a   Van Der Sterre, Marianne L T ^a   Eeltink, Corien M ^a   Fichtinger Schepman, Anne Marie J ^b   Vermorken, Jan B ^a   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; KIDNEY; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASMS;

EID: 0030944758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Van der Vijgh, W. J. F., and Peters, G. J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin. Oncol., 21: 2-7, 1994.
2. Glover, D., Grabelsky, S., Fox, K., Weiler, C., Cannon, L., and Glick, J. Clinical trials of WR-2721 and cis-platinum. Int. J. Radiat. Oncol. Biol. Phys., 16: 1201-1204, 1989.
3. Betticher, D. C., Anderson, H., Ranson, M., Meely, K., Oster, W., and Thatcher, N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised Phase II study. Br. J. Cancer, 72: 1551-1555, 1995.
4. Brown, D. Q., Graham, W. J., Mackenzie, L. J., Pittock, J. W., and Shaw, L. M. Can WR-2721 be improved upon? Pharmacol. Ther., 39: 157-168, 1988.
5. Yuhas, J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. Cancer Res., 40: 1519-1524, 1980.
6. Valeriote, F., and Tolen, S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res., 42: 4330-4332, 1982.
7. Millar, J. L., McElwain, T. J., Clutterbuck, R. D., and Wist, E. A. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am. J. Clin. Oncol., 5: 321-328, 1982.
8. Treskes, M., Boven, E. Van de Loosdrecht, A. A., and Wijffels, J. F. A. M. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur. J. Cancer, 30A: 183-187, 1994.
9. Korst, A. E. C., Boven, E., Van der Sterre, M. L. T., Fichtinger-Schepman, A. M. J., and Van der Vijgh, W. J. F. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Br. J. Cancer, in press, 1997.
10. Blommaert, F. A., Van Dijk-Knijnenburg, H. C. M., Dijt, F. J., Den Engelse, L., Baan, R. A., Berends, F., and Fichtinger-Schepman, A. M. J. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry, 34: 8474-8480, 1995.
11. Vermorken, J. B., Punt, C. J. A., Eeltink, C. M., Van Maanen, L., Korst, A. E. C., Oster, W., Kwakkelstein, M. O., and Van der Vijgh, W. J. F. Phase I trial of carboplatin and amifostine (WR-2721). Proc. Am. Assoc. Cancer Res., 36: 1432, 1995.
12. Korst, A. E. C., Gall, H. E., Vermorken, J. B., and Van der Vijgh, W. J. F. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother. Pharmacol., 39: 162-166, 1997.
13. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
14. Fichtinger-Schepman, A. M. J., Van Oosterom, A. T., Lohman, P. H. M., and Berends, F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunocytochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res., 47: 3000-3004, 1987.
15. Fichtinger-Schepman, A. M. J., Van Dijk-Knijnenburg, H. C. M., Dijt, F. J., Van der Velde-Visser, S. D., Berends, F., and Baan, R. A. Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. J. Inorg. Chem., 58: 177-191, 1995.
16. Van der Vijgh, W. J. F. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet., 21: 242-261, 1991.
17. Elferink, F., Van der Vijgh, W. J. F., Klein, I., Vermorken, J. B., Gall, H. E., and Pinedo, H. M. Pharmacokinetics of carboplatin after iv administration. Cancer Treat. Rep., 71: 1231-1237, 1987.
18. Vermorken, J. B., Van der Vijgh, W. J. F., Klein, I., Hart, A. M. M., Gall, H. E., and Pinedo, H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin. Pharmacol. Ther., 39: 136-144, 1986.
19. Budd, G. T., Ganapathi, R., Bauer, L., Murthy, S., Adelstein, D., Weick, J., Gibson, V., McLain, D., Sergi, J., and Bukowski, R. M. Phase I study of WR-2721 and carboplatin. Eur. J. Cancer, 29A: 1122-1127, 1993.
20. Vermorken, J. B., Punt, C. J. A., Eeltink, C. M., Van Maanen, L., Oster, W., Van Houten, M. D., and Van der Vijgh, W. J. F. Bone marrow protection by amifostine in patients treated with carboplatin: a Phase I study. Eur. J. Cancer, 30A (Suppl. 5): S200, 1995.